South Korea · Delayed Price · Currency is KRW Whan In Pharm Statistics
Total Valuation
Whan In Pharm has a market cap or net worth of KRW 176.33 billion. The enterprise value is 131.26 billion.
| Market Cap | 176.33B |
| Enterprise Value | 131.26B |
Important Dates
The next estimated earnings date is Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Whan In Pharm has 15.27 million shares outstanding.
| Current Share Class | 15.27M |
| Shares Outstanding | 15.27M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 28.36% |
| Owned by Institutions (%) | 14.21% |
| Float | 10.94M |
Valuation Ratios
The trailing PE ratio is 10.75 and the forward PE ratio is 10.64.
| PE Ratio | 10.75 |
| Forward PE | 10.64 |
| PS Ratio | 0.68 |
| PB Ratio | 0.46 |
| P/TBV Ratio | 0.48 |
| P/FCF Ratio | 21.01 |
| P/OCF Ratio | 11.96 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.41, with an EV/FCF ratio of 15.64.
| EV / Earnings | 8.00 |
| EV / Sales | 0.51 |
| EV / EBITDA | 5.41 |
| EV / EBIT | 8.97 |
| EV / FCF | 15.64 |
Financial Position
The company has a current ratio of 4.91, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.91 |
| Quick Ratio | 2.80 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.04 |
| Debt / FCF | 0.10 |
| Interest Coverage | 553.75 |
Financial Efficiency
Return on equity (ROE) is 4.38% and return on invested capital (ROIC) is 2.36%.
| Return on Equity (ROE) | 4.38% |
| Return on Assets (ROA) | 2.08% |
| Return on Invested Capital (ROIC) | 2.36% |
| Return on Capital Employed (ROCE) | 3.66% |
| Revenue Per Employee | 427.61M |
| Profits Per Employee | 27.12M |
| Employee Count | 605 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 2.24 |
Taxes
In the past 12 months, Whan In Pharm has paid 849.69 million in taxes.
| Income Tax | 849.69M |
| Effective Tax Rate | 4.92% |
Stock Price Statistics
The stock price has decreased by -12.90% in the last 52 weeks. The beta is 0.23, so Whan In Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | -12.90% |
| 50-Day Moving Average | 10,892.00 |
| 200-Day Moving Average | 11,537.45 |
| Relative Strength Index (RSI) | 62.93 |
| Average Volume (20 Days) | 61,153 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Whan In Pharm had revenue of KRW 258.70 billion and earned 16.41 billion in profits. Earnings per share was 1,074.45.
| Revenue | 258.70B |
| Gross Profit | 85.60B |
| Operating Income | 14.18B |
| Pretax Income | 17.26B |
| Net Income | 16.41B |
| EBITDA | 23.81B |
| EBIT | 14.18B |
| Earnings Per Share (EPS) | 1,074.45 |
Balance Sheet
The company has 45.95 billion in cash and 872.93 million in debt, giving a net cash position of 45.07 billion or 2,952.40 per share.
| Cash & Cash Equivalents | 45.95B |
| Total Debt | 872.93M |
| Net Cash | 45.07B |
| Net Cash Per Share | 2,952.40 |
| Equity (Book Value) | 380.48B |
| Book Value Per Share | 24,921.78 |
| Working Capital | 163.36B |
Cash Flow
In the last 12 months, operating cash flow was 14.74 billion and capital expenditures -6.35 billion, giving a free cash flow of 8.39 billion.
| Operating Cash Flow | 14.74B |
| Capital Expenditures | -6.35B |
| Free Cash Flow | 8.39B |
| FCF Per Share | 549.87 |
Margins
Gross margin is 33.09%, with operating and profit margins of 5.48% and 6.34%.
| Gross Margin | 33.09% |
| Operating Margin | 5.48% |
| Pretax Margin | 6.67% |
| Profit Margin | 6.34% |
| EBITDA Margin | 9.20% |
| EBIT Margin | 5.48% |
| FCF Margin | 3.25% |
Dividends & Yields
This stock pays an annual dividend of 300.00, which amounts to a dividend yield of 2.60%.
| Dividend Per Share | 300.00 |
| Dividend Yield | 2.60% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 27.91% |
| Buyback Yield | n/a |
| Shareholder Yield | 2.60% |
| Earnings Yield | 9.31% |
| FCF Yield | 4.76% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 14, 2010. It was a forward split with a ratio of 2.
| Last Split Date | Apr 14, 2010 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Whan In Pharm has an Altman Z-Score of 4.68 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.68 |
| Piotroski F-Score | 5 |